Key facts
- NeXtGen Biologics’s last known valuation is $6.6M (Nov 2015).
- It has raised $6.7M across 2 recorded rounds; the latest was Seed Round ($2.2M) in Dec 2018.
- Notable investors include Brian Lipke, Elad Levy, Gerald Lippes, Jerry Jacobs, Mark Hamister — 8 tracked in total.
- NeXtGen Biologics has filed 7 Form Ds with the SEC since 2014, most recently Sep 2025 ($130K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for NeXtGen Biologics
Funding rounds
2 roundsAbout NeXtGen Biologics
Developer of extracellular matrix biomaterial products designed to harness axolotl-derived extracellular matrix components for tissue regeneration. The company offers a collagen wound matrix sourced from the axolotl's extracellular matrix to better manage complex conditions seen in general surgery, trauma, cardiovascular diseases, neurosurgery, orthopedics, and ophthalmology, enabling clinicians treating partial and full-thickness wounds to support healing and improve the wound environment.
- Sector
- Healthcare
- HQ
- Alachua, FL, United States
- Founded
- 2014
- Employees
- 7
- Website
- nextgenbiologics.com/
- Ownership
- Privately Held (backing)
NeXtGen Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeXtGen Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeXtGen Biologics in its N-PORT filings yet. We sweep new filings monthly.